Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson’s Disease: A Randomized, Placebo-Controlled, Phase 1 Study

Background: Immunotherapies targeting α-synuclein aim to limit its extracellular spread in the brain and prevent progression of pathology in Parkinson’s disease (PD). PD03A is a specific active immunotherapy (SAIT) involving immunization with a short peptide formulation. Objective: This phase 1 stud...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Werner Poewe, Dieter Volc, Klaus Seppi, Rossella Medori, Petra Lührs, Alexandra Kutzelnigg, Atbin Djamshidian, Caroline Thun-Hohenstein, Wassilios G. Meissner, Olivier Rascol, Achim Schneeberger, Günther Staffler, Roberto deMarzi, Beatrice Heim, Stephanie Mangesius, Raphaela Stolz, Katarzyna Wachowicz, Constanze Riha, Vera Bürger, Gergana Galabova
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	SAGE Publishing 2021-08-01
Schriftenreihe:	Journal of Parkinson’s Disease
Online-Zugang:	https://doi.org/10.3233/JPD-212594
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!